IM Cannabis Corp. (IMCC)
USD 1.8
(-1.1%)
USD 1.8
(-1.1%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.79 Million CAD | 53.89% |
| 2022 | -26.4 Million CAD | 31.21% |
| 2021 | -38.38 Million USD | -365.6% |
| 2020 | -8.24 Million CAD | -24.12% |
| 2019 | -6.64 Million CAD | -315.47% |
| 2018 | 3.08 Million CAD | 2566.99% |
| 2017 | -124.97 Thousand CAD | -719.48% |
| 2016 | -15.25 Thousand CAD | 65.71% |
| 2015 | -44.47 Thousand CAD | 80.39% |
| 2014 | -226.78 Thousand CAD | -3.57% |
| 2013 | -218.96 Thousand CAD | 27.62% |
| 2012 | -302.5 Thousand CAD | 42.08% |
| 2011 | -522.29 Thousand CAD | 22.71% |
| 2010 | -675.72 Thousand CAD | 48.82% |
| 2009 | -1.32 Million CAD | 14.78% |
| 2008 | -1.54 Million CAD | -321.98% |
| 2007 | -367.11 Thousand CAD | 32.4% |
| 2006 | -543.05 Thousand CAD | 30.15% |
| 2005 | -777.45 Thousand CAD | -82.99% |
| 2004 | -424.86 Thousand CAD | 57.14% |
| 2003 | -991.23 Thousand CAD | 51.57% |
| 2002 | -2.04 Million CAD | -6018.87% |
| 2001 | 34.58 Thousand CAD | -68.81% |
| 2000 | 110.89 Thousand CAD | 10.89% |
| 1999 | 100 Thousand CAD | 0.0% |
| 1998 | 100 Thousand CAD | -83.33% |
| 1997 | 600 Thousand CAD | -45.45% |
| 1996 | 1.1 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.88 Million CAD | 48.7% |
| 2024 Q1 | -5.63 Million CAD | -9.0% |
| 2023 Q3 | -7.62 Million CAD | -335.33% |
| 2023 Q2 | -1.75 Million CAD | -258.41% |
| 2023 FY | -12.17 Million CAD | 53.89% |
| 2023 Q4 | -5.16 Million CAD | 32.28% |
| 2023 Q1 | 1.1 Million CAD | 110.33% |
| 2022 Q2 | -13.24 Million CAD | -69.74% |
| 2022 Q1 | -7.8 Million CAD | 33.44% |
| 2022 FY | -26.4 Million CAD | 31.21% |
| 2022 Q4 | -10.7 Million CAD | -93.79% |
| 2022 Q3 | -5.52 Million CAD | 58.27% |
| 2021 Q1 | -1.7 Million CAD | 73.29% |
| 2021 Q4 | -11.72 Million USD | 17.71% |
| 2021 Q2 | -10.71 Million CAD | -528.56% |
| 2021 FY | -38.38 Million USD | -365.6% |
| 2021 Q3 | -14.24 Million CAD | -32.92% |
| 2020 Q1 | 1.66 Million CAD | 164.22% |
| 2020 FY | -8.24 Million CAD | -24.12% |
| 2020 Q2 | 2.85 Million CAD | 71.57% |
| 2020 Q4 | -6.38 Million CAD | -851.27% |
| 2020 Q3 | -671 Thousand CAD | -123.5% |
| 2019 Q1 | -1.3 Million CAD | -6827.97% |
| 2019 Q4 | -2.59 Million CAD | -5.58% |
| 2019 Q3 | -2.45 Million CAD | -731.86% |
| 2019 FY | -6.64 Million CAD | -315.47% |
| 2019 Q2 | -295 Thousand CAD | 77.45% |
| 2018 Q2 | -60.94 Thousand CAD | -107.51% |
| 2018 Q4 | -18.88 Thousand CAD | -101.1% |
| 2018 Q1 | 812 Thousand CAD | 4116.02% |
| 2018 FY | 3.08 Million CAD | 2566.99% |
| 2018 Q3 | 1.71 Million CAD | 2915.84% |
| 2017 Q3 | -10.37 Thousand CAD | -627.72% |
| 2017 FY | -124.97 Thousand CAD | -719.48% |
| 2017 Q1 | -15.25 Thousand CAD | 0.0% |
| 2017 Q2 | -1425.00 CAD | 90.66% |
| 2017 Q4 | -20.21 Thousand CAD | -94.98% |
| 2016 FY | -15.25 Thousand CAD | 65.71% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 FY | -44.47 Thousand CAD | 80.39% |
| 2014 Q1 | -28.12 Thousand CAD | 60.61% |
| 2014 Q3 | -76.64 Thousand CAD | -166.31% |
| 2014 Q4 | -35.03 Thousand CAD | 54.3% |
| 2014 Q2 | -28.78 Thousand CAD | -2.34% |
| 2014 FY | -226.78 Thousand CAD | -3.57% |
| 2013 Q4 | -71.39 Thousand CAD | -16.87% |
| 2013 Q2 | -58.35 Thousand CAD | 26.66% |
| 2013 Q1 | -79.56 Thousand CAD | -3.89% |
| 2013 Q3 | -61.08 Thousand CAD | -4.68% |
| 2013 FY | -218.96 Thousand CAD | 27.62% |
| 2012 Q4 | -76.58 Thousand CAD | -1.57% |
| 2012 Q1 | -120.63 Thousand CAD | -47.13% |
| 2012 Q2 | -70.94 Thousand CAD | 41.19% |
| 2012 Q3 | -75.4 Thousand CAD | -6.28% |
| 2012 FY | -302.5 Thousand CAD | 42.08% |
| 2011 Q4 | -81.99 Thousand CAD | 37.43% |
| 2011 Q3 | -131.04 Thousand CAD | 30.53% |
| 2011 Q2 | -188.62 Thousand CAD | 14.99% |
| 2011 Q1 | -221.88 Thousand CAD | -106.58% |
| 2011 FY | -522.29 Thousand CAD | 22.71% |
| 2010 Q4 | -107.4 Thousand CAD | 54.07% |
| 2010 Q1 | -300.03 Thousand CAD | 56.49% |
| 2010 Q2 | -112.59 Thousand CAD | 62.47% |
| 2010 Q3 | -233.84 Thousand CAD | -107.7% |
| 2010 FY | -675.72 Thousand CAD | 48.82% |
| 2009 Q4 | -689.63 Thousand CAD | -318.06% |
| 2009 Q2 | -165.02 Thousand CAD | 52.71% |
| 2009 Q1 | -348.94 Thousand CAD | -39.14% |
| 2009 FY | -1.32 Million CAD | 14.78% |
| 2009 Q3 | -164.96 Thousand CAD | 0.04% |
| 2008 Q4 | -250.78 Thousand CAD | -104.65% |
| 2008 Q3 | -122.54 Thousand CAD | 86.56% |
| 2008 Q2 | -912.13 Thousand CAD | -767.41% |
| 2008 FY | -1.54 Million CAD | -321.98% |
| 2008 Q1 | -105.15 Thousand CAD | 15.8% |
| 2007 Q2 | -62.91 Thousand CAD | 79.69% |
| 2007 FY | -367.11 Thousand CAD | 32.4% |
| 2007 Q1 | -309.74 Thousand CAD | -464.6% |
| 2007 Q4 | -124.89 Thousand CAD | -55.49% |
| 2007 Q3 | -80.32 Thousand CAD | -27.67% |
| 2006 Q4 | -54.86 Thousand CAD | 53.38% |
| 2006 Q3 | -117.67 Thousand CAD | -93.65% |
| 2006 FY | -543.05 Thousand CAD | 30.15% |
| 2006 Q1 | -532.63 Thousand CAD | -786.83% |
| 2006 Q2 | -60.76 Thousand CAD | 88.59% |
| 2005 FY | -777.45 Thousand CAD | -82.99% |
| 2005 Q4 | -60.06 Thousand CAD | 40.3% |
| 2005 Q3 | -100.59 Thousand CAD | -19.54% |
| 2005 Q2 | -84.15 Thousand CAD | 57.15% |
| 2005 Q1 | -196.37 Thousand CAD | -242.76% |
| 2004 Q1 | -196.22 Thousand CAD | 68.69% |
| 2004 FY | -424.86 Thousand CAD | 57.14% |
| 2004 Q2 | -83.45 Thousand CAD | 57.47% |
| 2004 Q3 | -87.73 Thousand CAD | -5.13% |
| 2004 Q4 | -57.29 Thousand CAD | 34.7% |
| 2003 Q2 | -57.74 Thousand CAD | 76.78% |
| 2003 Q3 | -115.64 Thousand CAD | -100.26% |
| 2003 Q1 | -248.73 Thousand CAD | -308.24% |
| 2003 FY | -991.23 Thousand CAD | 51.57% |
| 2003 Q4 | -626.73 Thousand CAD | -441.94% |
| 2002 FY | -2.04 Million CAD | -6018.87% |
| 2002 Q3 | -659.38 Thousand CAD | -1111.77% |
| 2002 Q1 | -38.54 Thousand CAD | -507.59% |
| 2002 Q4 | -60.92 Thousand CAD | 90.76% |
| 2002 Q2 | -54.41 Thousand CAD | -41.17% |
| 2001 Q4 | 9457.00 CAD | 29.55% |
| 2001 Q2 | 17.82 Thousand CAD | 172.53% |
| 2001 FY | 34.58 Thousand CAD | -68.81% |
| 2001 Q1 | 6541.00 CAD | -62.23% |
| 2001 Q3 | 7300.00 CAD | -59.05% |
| 2000 Q1 | -500 Thousand CAD | -600.0% |
| 2000 Q4 | 17.31 Thousand CAD | 1731800.0% |
| 2000 Q3 | 1.00 CAD | -100.0% |
| 2000 Q2 | 100 Thousand CAD | 120.0% |
| 2000 FY | 110.89 Thousand CAD | 10.89% |
| 1999 Q3 | 100 Thousand CAD | 0.0% |
| 1999 FY | 100 Thousand CAD | 0.0% |
| 1999 Q4 | 100 Thousand CAD | 0.0% |
| 1999 Q2 | 100 Thousand CAD | 200.0% |
| 1999 Q1 | -100 Thousand CAD | -200.0% |
| 1998 Q3 | 100 Thousand CAD | 0.0% |
| 1998 FY | 100 Thousand CAD | -83.33% |
| 1998 Q4 | 100 Thousand CAD | 0.0% |
| 1998 Q1 | -100 Thousand CAD | -133.33% |
| 1998 Q2 | 100 Thousand CAD | 200.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 FY | 600 Thousand CAD | -45.45% |
| 1997 Q4 | 300 Thousand CAD | 50.0% |
| 1996 FY | 1.1 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Clever Leaves Holdings Inc. | -15.59 Million USD | 17.968% |
| Alvotech | -354.86 Million USD | 96.395% |
| Alimera Sciences, Inc. | -1.47 Million USD | -769.613% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 127.234% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 15.296% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 90.72% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -143.472% |
| Bright Green Corporation | -8.89 Million USD | -43.87% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 107.662% |
| Cosmos Health Inc. | -21.83 Million USD | 41.405% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -105.963% |
| Cronos Group Inc. | -81.37 Million USD | 84.28% |
| Phibro Animal Health Corporation | 53.31 Million USD | 123.993% |
| Journey Medical Corporation | -2.07 Million USD | -517.077% |
| Dynavax Technologies Corporation | -37.02 Million USD | 65.453% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -50.088% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -194.997% |
| Biofrontera Inc. | -22.67 Million USD | 43.59% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 67.328% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 237.091% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 114.59% |
| OptiNose, Inc. | -22.74 Million USD | 43.766% |
| Procaps Group, S.A. | 38.97 Million USD | 132.823% |
| ProPhase Labs, Inc. | -21.61 Million USD | 40.813% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 201.267% |
| Radius Health, Inc. | -3.92 Million USD | -225.911% |
| Rockwell Medical, Inc. | -6.67 Million USD | -91.784% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -167.319% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -167.319% |
| SCYNEXIS, Inc. | 72.66 Million USD | 117.603% |
| Safety Shot Inc | -12.18 Million USD | -4.989% |
| SIGA Technologies, Inc. | 83.62 Million USD | 115.298% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -172.112% |
| Silver Spike Investment Corp. | 7.34 Million USD | 274.275% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -117.094% |
| Shineco, Inc. | -17.06 Million USD | 25.043% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -408.584% |
| Theratechnologies Inc. | -10.62 Million USD | -20.373% |
| Talphera, Inc. | -16.88 Million USD | 24.258% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -262.711% |
| Harrow Health, Inc. | 580 Thousand USD | 2305.517% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 106.12% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -142.779% |
| Tilray Brands, Inc. | -174.74 Million USD | 92.68% |
| DURECT Corporation | -36.88 Million USD | 65.318% |
| Incannex Healthcare Limited | -30.04 Million USD | 57.418% |
| Alpha Teknova, Inc. | -35.56 Million USD | 64.03% |
| Procaps Group S.A. | 52.32 Million USD | 124.448% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 6.061% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 91.974% |
| Viatris Inc. | 766.2 Million USD | 101.67% |
| PetIQ, Inc. | 60.01 Million USD | 121.315% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 105.098% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 202.132% |
| Assertio Holdings, Inc. | -243.53 Million USD | 94.747% |
| Embecta Corp. | 221.5 Million USD | 105.775% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -170.06% |
| PainReform Ltd. | -9.58 Million USD | -33.472% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 36.2% |
| Alvotech | -354.86 Million USD | 96.395% |
| Hempacco Co., Inc. | -8.81 Million USD | -45.161% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 123.931% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 103.508% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 91.777% |
| Kamada Ltd. | 10.06 Million USD | 227.107% |
| Indivior PLC | -4 Million USD | -219.8% |
| Evoke Pharma, Inc. | -7.43 Million USD | -72.146% |
| Flora Growth Corp. | -50.35 Million USD | 74.596% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 36.2% |
| Evolus, Inc. | -49.23 Million USD | 74.017% |
| HUTCHMED (China) Limited | 18.37 Million USD | 169.616% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 106.494% |
| Akanda Corp. | -10.05 Million USD | -27.266% |